Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics. It targets both incretin and glucagon pathways, which may provide enhanced metabolic benefits including weight loss and improved glucose control.

While tirzepatide is a dual GLP-1/GIP agonist, Mazdutide is a dual GLP-1/glucagon agonist. The glucagon component may provide additional benefits for energy expenditure and hepatic fat reduction compared to GIP-based approaches.

Phase 3 trials are studying weekly subcutaneous doses of 4 mg, 6 mg, and 9 mg with dose escalation schedules. The calculator helps determine injection volumes based on your specific vial concentration.